Esperion recalls NEXLIZET (bempedoic acid and ezetimibe) tablets
FDA Class III
FDA classified this recall as Class III: the product is unlikely to cause health problems but breaks the agency's rules (a labeling mistake, for example).
- Hazard
- Failed dissolution specifications: out-of-specification bempedoic acid dissolution at the 0-month timepoint.
- Products
-
- NEXLIZET (bempedoic acid and ezetimibe) tablets
- Company
- Esperion
- Where it was sold
-
Nationwide in the USA
Nationwide
- Units affected
- 3,480 30-count bottles
- About this recall
- NEXLIZET (bempedoic acid and ezetimibe) tablets, 180 mg/10 mg, 30-count bottle, Rx only, Manufactured for: Esperion Therapeutics, Ann Arbor, MI 48108, NDC 72426-818-03